Jordi Bruix
www.bclc.cat
0000-0002-9826-0753
197 papers found
Refreshing results…
Corrigendum to “Diagnosis and staging of hepatocellular carcinoma (HCC): Current guidelines” [Eur. J. Radiol. 101 (2018) 72–81]
Diagnosis of Hepatic Nodules in Patients at Risk for Hepatocellular Carcinoma: LI-RADS Probability Versus Certainty
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules
Analysis of single-nucleotide polymorphisms (SNPs) in the phase III RESORCE trial of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC)
Clinicopathological evaluation of skin lesions (SL) in patients with hepatocellular carcinoma (HCC) treated with sorafenib
Corrigendum to “Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies” [J hepatol 67 (2017) 999–1008]
Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Liver metastases from gastric adenocarcinoma mimicking multinodular hepatocellular carcinoma
Locoregional versus systemic therapy — robust positive data remain elusive
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Diagnosis and staging of hepatocellular carcinoma (HCC): current guidelines
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
Lenvatinib: can a non-inferiority trial change clinical practice?
Reply to: “Predictors of sorafenib benefit in patients with hepatocellular carcinoma”
Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria (Barcelona Clinic Liver Cancer extended criteria)
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events
Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study
Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma
Missing publications? Search for publications with a matching author name.